Is TRAX or XENE more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets First Tracks Biotherapeutics N/A N/A N/A Xenon Pharmaceuticals N/A -43.98% -41.72%

Does the media prefer TRAX or PTCT?

In the previous week, First Tracks Biotherapeutics had 14 more articles in the media than PTC Therapeutics. MarketBeat recorded 18 mentions for First Tracks Biotherapeutics and 4 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.34 beat First Tracks Biotherapeutics' score of 0.02 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment First Tracks Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral PTC Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TVTX or TRAX?

In the previous week, First Tracks Biotherapeutics had 3 more articles in the media than Travere Therapeutics. MarketBeat recorded 18 mentions for First Tracks Biotherapeutics and 15 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.14 beat First Tracks Biotherapeutics' score of 0.02 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive First Tracks Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

First Tracks Biotherapeutics (TRAX) Competitors

$44.04 +0.01 (+0.02%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$44.10 +0.05 (+0.12%)

As of 08/14/2026 07:34 PM Eastern

Compare

TRAX vs. XENE, PTCT, KNSA, LGND, and TVTX

Should you buy First Tracks Biotherapeutics stock or one of its competitors? First Tracks Biotherapeutics's main competitors and comparable companies include Xenon Pharmaceuticals (XENE), PTC Therapeutics (PTCT), Kiniksa Pharmaceuticals International (KNSA), Ligand Pharmaceuticals (LGND), and Travere Therapeutics (TVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does First Tracks Biotherapeutics compare to Xenon Pharmaceuticals?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

First Tracks Biotherapeutics has higher earnings, but lower revenue than Xenon Pharmaceuticals. First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
Xenon Pharmaceuticals	$7.50M	803.65	-$345.91M	-$4.74	N/A

First Tracks Biotherapeutics' return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

In the previous week, Xenon Pharmaceuticals had 5 more articles in the media than First Tracks Biotherapeutics. MarketBeat recorded 23 mentions for Xenon Pharmaceuticals and 18 mentions for First Tracks Biotherapeutics. Xenon Pharmaceuticals' average media sentiment score of 1.02 beat First Tracks Biotherapeutics' score of 0.02 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
First Tracks Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

First Tracks Biotherapeutics currently has a consensus price target of $60.50, indicating a potential upside of 37.38%. Xenon Pharmaceuticals has a consensus price target of $77.13, indicating a potential upside of 23.71%. Given First Tracks Biotherapeutics' higher possible upside, analysts plainly believe First Tracks Biotherapeutics is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Xenon Pharmaceuticals beats First Tracks Biotherapeutics on 9 of the 13 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to PTC Therapeutics?

First Tracks Biotherapeutics (NASDAQ:TRAX) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, First Tracks Biotherapeutics had 14 more articles in the media than PTC Therapeutics. MarketBeat recorded 18 mentions for First Tracks Biotherapeutics and 4 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.34 beat First Tracks Biotherapeutics' score of 0.02 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
First Tracks Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
PTC Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PTC Therapeutics has higher revenue and earnings than First Tracks Biotherapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than First Tracks Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
PTC Therapeutics	$1.73B	3.46	$682.64M	-$0.58	N/A

First Tracks Biotherapeutics presently has a consensus price target of $60.50, suggesting a potential upside of 37.38%. PTC Therapeutics has a consensus price target of $98.55, suggesting a potential upside of 37.44%. Given PTC Therapeutics' higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64

First Tracks Biotherapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -3.80%. First Tracks Biotherapeutics' return on equity of 0.00% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
PTC Therapeutics	-3.80%	-362.45%	-1.32%

Summary

First Tracks Biotherapeutics and PTC Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to Kiniksa Pharmaceuticals International?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Kiniksa Pharmaceuticals International has higher revenue and earnings than First Tracks Biotherapeutics. First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
Kiniksa Pharmaceuticals International	$677.56M	8.84	$59.01M	$0.97	79.12

In the previous week, First Tracks Biotherapeutics had 14 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 18 mentions for First Tracks Biotherapeutics and 4 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.22 beat First Tracks Biotherapeutics' score of 0.02 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
First Tracks Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

First Tracks Biotherapeutics currently has a consensus target price of $60.50, suggesting a potential upside of 37.38%. Kiniksa Pharmaceuticals International has a consensus target price of $87.38, suggesting a potential upside of 13.84%. Given First Tracks Biotherapeutics' higher probable upside, equities analysts clearly believe First Tracks Biotherapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to First Tracks Biotherapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat First Tracks Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

Summary

Kiniksa Pharmaceuticals International beats First Tracks Biotherapeutics on 10 of the 12 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Ligand Pharmaceuticals has higher revenue and earnings than First Tracks Biotherapeutics. First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	21.91	$124.45M	$9.35	31.51
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

In the previous week, First Tracks Biotherapeutics had 4 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 18 mentions for First Tracks Biotherapeutics and 14 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.39 beat First Tracks Biotherapeutics' score of 0.02 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
First Tracks Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ligand Pharmaceuticals has a net margin of 67.88% compared to First Tracks Biotherapeutics' net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 20.06% beat First Tracks Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
First Tracks Biotherapeutics	N/A	N/A	N/A

Ligand Pharmaceuticals currently has a consensus price target of $335.75, indicating a potential upside of 13.97%. First Tracks Biotherapeutics has a consensus price target of $60.50, indicating a potential upside of 37.38%. Given First Tracks Biotherapeutics' higher probable upside, analysts plainly believe First Tracks Biotherapeutics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

Ligand Pharmaceuticals beats First Tracks Biotherapeutics on 11 of the 13 factors compared between the two stocks.

How does First Tracks Biotherapeutics compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

In the previous week, First Tracks Biotherapeutics had 3 more articles in the media than Travere Therapeutics. MarketBeat recorded 18 mentions for First Tracks Biotherapeutics and 15 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.14 beat First Tracks Biotherapeutics' score of 0.02 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
First Tracks Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Travere Therapeutics currently has a consensus price target of $61.67, indicating a potential downside of 0.76%. First Tracks Biotherapeutics has a consensus price target of $60.50, indicating a potential upside of 37.38%. Given First Tracks Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe First Tracks Biotherapeutics is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

First Tracks Biotherapeutics has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than First Tracks Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	11.94	-$25.55M	-$0.46	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

First Tracks Biotherapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. First Tracks Biotherapeutics' return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-7.35%	-55.15%	-6.88%
First Tracks Biotherapeutics	N/A	N/A	N/A

Summary

First Tracks Biotherapeutics beats Travere Therapeutics on 7 of the 11 factors compared between the two stocks.

Get First Tracks Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRAX vs. The Competition

Export

Metric	First Tracks Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.54B	$3.72B	$7.04B	$13.07B
Dividend Yield	N/A	3.69%	2.57%	10.65%
P/E Ratio	-23.93	10.77	270.98	25.37
Price / Sales	N/A	1,347.12	618.37	106.15
Price / Cash	N/A	101.42	75.70	53.27
Price / Book	9.10	16.78	12.92	6.21
Net Income	N/A	-$13.32M	$3.45B	$347.71M
7 Day Performance	-2.85%	1.76%	1.16%	1.08%
1 Month Performance	21.89%	1.14%	1.37%	0.82%
1 Year Performance	N/A	54.35%	62.53%	20.99%

First Tracks Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRAX First Tracks Biotherapeutics	3.5664 of 5 stars	$44.04 +0.0%	$60.50 +37.4%	N/A	$1.54B	N/A	N/A	N/A	Trending News Earnings Report Analyst Forecast Analyst Revision
XENE Xenon Pharmaceuticals	3.2529 of 5 stars	$62.33 -3.0%	$77.13 +23.8%	+64.3%	$6.03B	$7.50M	N/A	210	Positive News Insider Trade Analyst Revision
PTCT PTC Therapeutics	3.3929 of 5 stars	$71.72 -0.4%	$98.55 +37.4%	+47.2%	$5.99B	$1.01B	N/A	1,410	Analyst Forecast
KNSA Kiniksa Pharmaceuticals International	4.1519 of 5 stars	$76.45 -1.8%	$87.38 +14.3%	+130.6%	$5.97B	$677.56M	78.87	220	Positive News Analyst Downgrade
LGND Ligand Pharmaceuticals	3.7219 of 5 stars	$294.76 +2.1%	$336.57 +14.2%	+91.6%	$5.86B	$268.09M	31.45	80	Positive News Analyst Upgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRAX) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

First Tracks Biotherapeutics (TRAX) Competitors

TRAX vs. XENE, PTCT, KNSA, LGND, and TVTX

How does First Tracks Biotherapeutics compare to Xenon Pharmaceuticals?

Summary

How does First Tracks Biotherapeutics compare to PTC Therapeutics?

Summary

How does First Tracks Biotherapeutics compare to Kiniksa Pharmaceuticals International?

Summary

How does First Tracks Biotherapeutics compare to Ligand Pharmaceuticals?

Summary

How does First Tracks Biotherapeutics compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAX vs. The Competition

First Tracks Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

First Tracks Biotherapeutics (TRAX) Competitors

TRAX vs. XENE, PTCT, KNSA, LGND, and TVTX

How does First Tracks Biotherapeutics compare to Xenon Pharmaceuticals?

Do insiders and institutionals believe in TRAX or XENE?

Which has higher valuation & earnings, TRAX or XENE?

Is TRAX or XENE more profitable?

Does the media refer more to TRAX or XENE?

Do analysts prefer TRAX or XENE?

Summary

How does First Tracks Biotherapeutics compare to PTC Therapeutics?

Does the media prefer TRAX or PTCT?

Which has stronger earnings and valuation, TRAX or PTCT?

Do analysts prefer TRAX or PTCT?

Is TRAX or PTCT more profitable?

Summary

How does First Tracks Biotherapeutics compare to Kiniksa Pharmaceuticals International?

Which has stronger valuation & earnings, TRAX or KNSA?

Does the media prefer TRAX or KNSA?

Do insiders and institutionals have more ownership in TRAX or KNSA?

Do analysts recommend TRAX or KNSA?

Is TRAX or KNSA more profitable?

Summary

How does First Tracks Biotherapeutics compare to Ligand Pharmaceuticals?

Which has preferable earnings & valuation, LGND or TRAX?

Does the media prefer LGND or TRAX?

Do insiders and institutionals believe in LGND or TRAX?

Is LGND or TRAX more profitable?

Do analysts recommend LGND or TRAX?

Summary

How does First Tracks Biotherapeutics compare to Travere Therapeutics?

Does the media favor TVTX or TRAX?

Do analysts rate TVTX or TRAX?

Which has stronger earnings & valuation, TVTX or TRAX?

Is TVTX or TRAX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAX vs. The Competition

First Tracks Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools